Rishi R Lulla

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9148667/publications.pdf

Version: 2024-02-01

46 papers	1,939 citations	394286 19 h-index	315616 38 g-index
48 all docs	48 docs citations	48 times ranked	3838 citing authors

#	Article	IF	Citations
1	Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. Scientific Reports, 2021, 11, 5098.	1.6	31
2	Synergistic imipridoneâ€based drug combinations for treatment of pediatric H3K27M mutant diffuse intrinsic pontine glioma (DIPG). FASEB Journal, 2021, 35, .	0.2	2
3	HGG-42. PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) SHOWS ROBUST RESPONSE TO IMIPRIDONE BASED COMBINATION THERAPY. Neuro-Oncology, 2021, 23, i26-i26.	0.6	0
4	EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia, 2021, 23, 792-810.	2.3	26
5	Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis. American Journal of Cancer Research, 2021, 11, 4607-4623.	1.4	2
6	Pediatric high-grade glioma resources from the Childrenâ€™s Brain Tumor Tissue Consortium. Neuro-Oncology, 2020, 22, 163-165.	0.6	29
7	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. Journal of Clinical Investigation, 2020, 130, 6325-6337.	3.9	70
8	DIPG-62. PRECLINICAL EVALUATION OF IMIPRIDONE-BASED COMBINATION THERAPIES IN PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2020, 22, iii299-iii299.	0.6	1
9	DDRE-10. IMMUNE PROFILES ASSOCIATE WITH OUTCOMES IN HLA-A*02:01+, H3.3K27M+ PATIENTS WITH DIFFUSE MIDLINE GLIOMAS TREATED WITH H3.3K27M PEPTIDE VACCINE COMBINED WITH POLY-ICLC: A PNOC REPORT. Neuro-Oncology, 2020, 22, ii63-ii63.	0.6	0
10	Transcriptional repressor REST drives lineage stageâ€“specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma. Science Signaling, 2019, 12, .	1.6	19
11	Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2019, 25, 5572-5583.	3.2	52
12	IMMU-01. NOVEL RNA-TARGETING STRATEGY FOR TREATING T CELL-DRIVEN IMMUNOSUPPRESSION IN HUMAN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2019, 21, ii92-ii93.	0.6	2
13	Improved neuropsychological outcomes following proton therapy relative to X-ray therapy for pediatric brain tumor patients. Neuro-Oncology, 2019, 21, 934-943.	0.6	51
14	Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro-Oncology, 2019, 21, 537-546.	0.6	61
15	Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2018, 40, 616-619.	0.3	1
16	DIPG-63. RADIATION DNA DAMAGE REPAIR INHIBITION BY GSK-J4 INDUCED CHROMATIN COMPACTION IN DIPG. Neuro-Oncology, 2018, 20, i61-i62.	0.6	0
17	RONC-22. IMPACT OF RADIOTHERAPY MODALITY ON NEUROPSYCHOLOGICAL OUTCOMES OF PEDIATRIC BRAIN TUMOR PATIENTS. Neuro-Oncology, 2018, 20, i179-i179.	0.6	0
18	PDTM-42. TARGETED INHIBITION OF BET BROMODOMAIN AND JMJD3 PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, vi212-vi213.	0.6	0

#	Article	IF	Citations
19	REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget, 2018, 9, 5233-5250.	0.8	12
20	Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Oncotarget, 2018, 9, 37112-37124.	0.8	44
21	Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nature Medicine, 2017, 23, 493-500.	15.2	332
22	Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathologica Communications, 2017, 5, 28.	2.4	127
23	Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib. Pediatric Dermatology, 2017, 34, 337-341.	0.5	11
24	Blood-brain barrierâ€“adapted precision medicine therapy for pediatric brain tumors. Translational Research, 2017, 188, 27.e1-27.e14.	2.2	12
25	IMMU-46. AÂsiRNA APPROACH FOR TARGETING IMMUNOSUPPRESSIVE IDO1 IN PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2017, 19, vi122-vi123.	0.6	0
26	Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro-Oncology, 2016, 18, now106.	0.6	73
27	EPT-19PHASE I TRIAL OF PALBOCICLIB, A CDK4/6 INHIBITOR IN CHILDREN WITH RETINOBLASTOMA PROTEIN (RB1) + RECURRENT CENTRAL NERVOUS SYSTEM (CNS) TUMORS (PBTC 042). Neuro-Oncology, 2016, 18, iii28.1-iii28.	0.6	1
28	TB-08MECHANISMS OF IMMUNE RESISTANCE IN PEDIATRIC POSTERIOR FOSSA TUMORS. Neuro-Oncology, 2016, 18, iii170.1-iii170.	0.6	0
29	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	7.7	191
30	Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro-Oncology, 2016, 18, 1319-1325.	0.6	108
31	Improving vaccine efficacy against malignant glioma. OncoImmunology, 2016, 5, e1196311.	2.1	16
32	Mutations in chromatin machinery and pediatric high-grade glioma. Science Advances, 2016, 2, e1501354.	4.7	69
33	Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110Î± inhibition. Oncotarget, 2016, 7, 33192-33201.	0.8	26
34	A Mouse Model of Human Primitive Neuroectodermal Tumors Resulting from Microenvironmentally-Driven Malignant Transformation of Orthotopically Transplanted Radial Glial Cells. PLoS ONE, 2015, 10, e0121707.	1.1	6
35	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84
36	Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. Journal of Neuro-Oncology, 2015, 121, 217-224.	1.4	20

#	Article	IF	Citations
37	Proton therapy and helical tomotherapy result in reduced dose deposition to the pancreas in the setting of cranio-spinal irradiation for medulloblastoma: Implications for reduced risk of diabetes mellitus in long-term survivors. Acta OncolÃ³gica, 2015, 54, 522-526.	0.8	14
38	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	5.1	147
39	Imaging findings of anaplastic astrocytoma in a child with maple syrup urine disease: a case report. Child's Nervous System, 2015, 31, 1625-1629.	0.6	0
40	Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. Oncotarget, 2014, 5, 8442-8451.	0.8	35
41	Symptomatic Cerebral Vasospasm Following Resection of a Medulloblastoma in a Child. Neurocritical Care, 2013, 18, 84-88.	1.2	12
42	Emergencies in Children and Young Adults with Central Nervous System Tumors. Clinical Pediatric Emergency Medicine, 2011, 12, 213-223.	0.4	3
43	Identification of Differentially Expressed MicroRNAs in Osteosarcoma. Sarcoma, 2011, 2011, 1-6.	0.7	123
44	Identification of MicroRNAs as Potential Prognostic Markers in Ependymoma. PLoS ONE, 2011, 6, e25114.	1.1	103
45	Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. Pediatric Blood and Cancer, 2010, 55, 141-144.	0.8	16
46	Longitudinal assessment of regional directed delivery in a rodent malignant glioma model. Journal of Neurosurgery: Pediatrics, 2009, 4, 592-598.	0.8	7